Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study
Keywords:
pulmonary fibrosis, pirfenidone, advanced sarcoidosis, DLCOReferences
Swigris JJ, Olson AL, Huie TJ et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011;183(11):1524-1530.
Nardi A, Brillet PY, Letoumelin P et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011;38(6):1368-1373.
Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest 2018;153(1):105-113.
Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16(Sep):149-173.
Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177(11):1248-1254.
Baughman RP, Shlobin OA, Wells AU et al. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 2018;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub;%2018 May 5.:72-78.
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159(1):179-187.
Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948-968.
Walsh SL, Wells AU, Sverzellati N et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014;2(2):123-130.
Wells AU, Desai SR, Rubens MB et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167(7):962-969.
Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007;132(1):207-213.
Patel AS, Siegert RJ, Creamer D et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013;68(1):57-65.
de Vries J, Michielsen H, van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004;9(Pt 3):279-291.
Patel AS, Siegert RJ, Keir GJ et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013;107(9):1438-1443.
Papiris SA, Daniil ZD, Malagari K et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005;99(6):755-761.
Jeny F, Uzunhan Y, Lacroix M et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med 2020;169:105997. doi: 10.1016/j.rmed.2020.105997. Epub@2020 May 12.:105997.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Robert P. Baughman, Rohit Gupta, Marc Judson, Elyse Lower, Surinder Birrinder, Jeffrey Stewart, Rebecca Reeves, Athol Wells

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.